For Amgen and Novartis, investing in the latest fund from Atlas Venture wasn't enough. The Cambridge, MA-based venture firm has struck separate agreements with the two major drugmakers to join forces on biotech startups.
Two years after leaving the biotech giant Genzyme, Henri Termeer has found increased demand for his expertise and personal resources from a growing crowd of startups in the Boston area and The Netherlands, he told FierceBiotech in an interview. Read more >>
A little more than a year ago, the startup crew at Lumena Pharmaceuticals was based in North Carolina and working on a new drug for diabetics. But things have changed. The company moved to San Diego, refocused its lead program on a rare liver disease and today announced that it had rounded up $23 million in Series A cash from a trio of venture groups.
Brace for more dour figures on venture investment in biotech. Despite some bright spots in life sciences venture investing, a new study finds that VC players in biotech and devices might struggle to sustain investment levels. And one of the few consolation prizes for the companies that won venture deals is that valuations inched up in 2012.
Boehringer Ingelheim Venture Fund, the VC unit of the Germany-based pharma group, has injected an undisclosed amount of capital into Eyevensys, which uses electro-transfer in a gene therapy approach to treat ocular diseases.
Astellas Pharma has wagered on antibody drug conjugate tech from the San Diego biotech startup Ambrx, paying $15 million upfront and committing up to $285 million more in their collaboration focused in oncology. And it's more proof that major pharma outfits are keen on the advantages of pairing targeted antibodies with potent drug payloads to treat cancer.
Boston startup Entrega is developing a novel drug-delivery capsule that could give the company a foothold in a $200 billion arena just begging for more needle-free options, paving the way for the more elegant delivery of treatments for diseases such as Parkinson's, cancer and arthritis.
Austin-based Savara Pharmaceuticals has rounded up $11.4 million in cash to fuel the upstart biotech through a key transition phase: taking its lead development program through a crucial proof-of-concept study that could leave the biotech on the threshold of a late-stage trial.
Bioscience entrepreneurship is alive in the Alamo City. After planting a flag in the unlikely locale of San Antonio, Silicon Valley-based incubator outfit InCube Labs has found $30 million from local private and public sources to hatch new life sciences startups.
Domain Associates has begun tapping its extensive biopharma network in search of products that could have a bright future in the Chinese market. The venture capital firm has partnered with a group of pharma consultants to create a new venture arm--Domain Elite--dedicated to creating a portfolio of new biopharma companies in China which will in-license drug and device technology for the Chinese market.